Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic profiling of highly- and lowly- metastasizing pancreatic ductal carcinoma cells [mRNAseq shNPTX1]

ABSTRACT: Transcriptomic profiling of highly- and lowly- metastasizing pancreatic ductal carcinoma cells [mRNAseq shNPTX1]

PROVIDER: PRJNA828602 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18840614.fastq.gz	Fastqsanger.gz
	SRR18840615.fastq.gz	Fastqsanger.gz
	SRR18840616.fastq.gz	Fastqsanger.gz
	SRR18840617.fastq.gz	Fastqsanger.gz
	SRR18840618.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 11

Similar Datasets

Transcriptomic profiling of highly- and lowly- metastasizing pancreatic ductal carcinoma cells [mRNAseq in vivo selection]

Project description:Transcriptomic profiling of highly- and lowly- metastasizing pancreatic ductal carcinoma cells [mRNAseq in vivo selection]

| PRJNA828601 | ENA

Transcriptomic profiling of highly- and lowly- metastasizing pancreatic ductal carcinoma cells [mRNAseq shNPTX1]

Project description:To interrogate transcriptomic changes in highly liver metastatic pancreatic ductal carcinoma cells as relative to their isogenic lowly metastatic cells

2024-04-20 | GSE201176 | GEO

Transcriptomic profiling of highly- and lowly- metastasizing pancreatic ductal carcinoma cells [mRNAseq in vivo selection]

Project description:To interrogate transcriptomic changes in highly liver metastatic pancreatic ductal carcinoma cells as relative to their isogenic lowly metastatic cells

2024-04-20 | GSE201175 | GEO

Transcriptomic profiling of highly- and lowly- metastasizing pancreatic ductal carcinoma cells

Project description:Transcriptomic profiling of highly- and lowly- metastasizing pancreatic ductal carcinoma cells

| PRJNA828598 | ENA

Transcriptomic profiling of highly- and lowly- metastasizing pancreatic ductal carcinoma cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-04-20 | GSE201177 | GEO

mRNA sequencing of highly and lowly metastatic human colorectal cancer PDXs

Project description:mRNA sequencing of highly and lowly metastatic human colorectal cancer PDXs

| PRJNA575218 | ENA

RNA-seq of Highly Metastatic and Lowly Metastatic 4T1 Single Clones Treated with Iron Chelator Deferasirox (DFX)

Project description:RNA-seq of Highly Metastatic and Lowly Metastatic 4T1 Single Clones Treated with Iron Chelator Deferasirox (DFX)

| PRJNA902387 | ENA

Tweak and non metastasizing thick melanoma

Project description:Road to metastasis:the TWEAK pathway as a discriminant between metastasizing and non-metastasizing thick melanomas

| PRJEB47586 | ENA

mRNASeq of glioma cells

Project description:mRNASeq of glioma cells

| PRJNA673900 | ENA

Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells

Project description:V600E being the most common mutation in BRAF, leads to constitutive activation of the MAPK signaling pathway. The majority of V600E BRAF positive melanoma patients treated with the BRAF inhibitor vemurafenib showed initial good clinical responses but relapsed due to acquired resistance to the drug. The aim of the present study was to identify possible biomarkers associated with the emergence of drug resistant melanoma cells. To this end we analyzed the differential gene expression of vemurafenib-sensitive and vemurafenib resistant brain and lung metastasizing melanoma cells. The major finding of this study is that the in vitro induction of vemurafenib resistance in melanoma cells is associated with an increased malignancy phenotype of these cells. Resistant cells expressed higher levels of genes coding for cancer stem cell markers (JARID1B, CD271 and Fibronectin) as well as genes involved in drug resistance (ABCG2), cell invasion and promotion of metastasis (MMP-1 and MMP-2). We also showed that drug-resistant melanoma cells adhere better to and transmigrate more efficiently through lung endothelial cells than drug-sensitive cells. The former cells also alter their microenvironment in a different manner from that of drug-sensitive cells. Biomarkers and molecular mechanisms associated with drug resistance may serve as targets for therapy of drug-resistant cancer.

2015-03-20 | GSE67088 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data